---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-016372"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:46:12.989876+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xilio completes $25M Gilead investment; XTX301 shows no DLTs in Phase 1; cash into Q3 2025

## Summary
- Completed $8.2M Gilead private placement (common + prefunded warrants), exhausting $25M stock purchase agreement.
- Preliminary Phase 1 data for XTX301 (IL-12) in 34 patients: no DLTs, no Grade 4/5 AEs, sustained IFN-gamma signaling.
- No measurable activated XTX301 in peripheral circulation; majority of AEs Grade 1/2 (flu-like, CRS, transaminitis).
- Cash runway guidance updated: existing cash + equivalents expected to fund operations into Q3 2025.
- Initial Phase 2 data for vilastobart (XTX101) + atezolizumab in MSS CRC to be presented at ASCO GI (Jan 2025).

## SEC filing metadata
- accession: 0001558370-24-016372
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837024016372/0001558370-24-016372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837024016372/xlo-20241218x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-016372
- JSON: https://secwatch.observer/filing/0001558370-24-016372.json
- Plain text: https://secwatch.observer/filing/0001558370-24-016372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.